Point72 Asset Management
RAPT

Point72 Asset Management’s RAPT Therapeutics RAPT Stock Holding History

Point72 Asset Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,185
Closed -$853K – 4356
2025
Q4 		$853K Buy
25,185
+12,807
+103% +$398K ﹤0.01% 2955
2025
Q3 		$319K Buy
+12,378
New +$162K ﹤0.01% 2054
2024
Q4 		– Sell
-65,653
Closed -$1.06M – 2385
2024
Q3 		$1.06M Sell
65,653
-22,760
-26% -$460K ﹤0.01% 1397
2024
Q2 		$2.16M Buy
88,413
+88,363
+176,726% +$4.08M 0.01% 1077
2024
Q1 		$3.59K Sell
50
-11,288
-100% -$1.57M ﹤0.01% 2110
2023
Q4 		$2.25M Sell
11,338
-17,150
-60% -$2.12M 0.01% 1163
2023
Q3 		$3.79M Buy
+28,488
New +$4.65M 0.01% 969
2023
Q2 		– Sell
-40,713
Closed -$5.98M – 2681
2023
Q1 		$5.98M Buy
+40,713
New +$8.23M 0.02% 709

Point72 Asset Management's RAPT Position: Q1 2026 in Review

Point72 Asset Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 25,185 shares — an estimated $853K sold.

Point72 Asset Management first reported a position in RAPT in Q1 2023 and held it in 8 quarters. The position peaked at $5.98M in Q1 2023. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • Point72 Asset Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 25,185 RAPT Therapeutics shares in Q1 2026, an estimated $853K.
  • Point72 Asset Management first reported a position in RAPT Therapeutics in Q1 2023 and held it in 8 quarters.
  • Point72 Asset Management's RAPT Therapeutics position peaked at $5.98M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.